Hetty Carraway, MD- Hematology and Medical Oncology- Cleveland Clinic
Hetty Carraway, MD, delivers a comprehensive discussion on immune-based and novel strategies to enhance outcomes for patients with myelodysplastic syndromes (MDS). The focus lies on unraveling the intricate relationship between the immune system and MDS pathogenesis, exploring immune interventions like immune checkpoint inhibitors (ICIs), and addressing challenges related to immune manipulation, mutational profiles, and the microenvironment.
The discourse underscores the necessity for continuous research, particularly within the context of an aging population and its implications for health outcomes. Hetty Carraway also delves into potential therapeutic avenues involving specific mutation targeting and inflammation pathways, emphasizing the nuanced interplay between genetics and the immune landscape in shaping disease progression. The overarching goal is to uncover strategies that disrupt clonal evolution and enhance treatment options, all presented by Hetty Carraway, MD.